Reindeer Medical announces the completion of the first patient enrollment and apheresis in the CT120 Phase I/II registered clinical study

Nanjing, Shanghai and San Francisco, November 10, 2021/PRNewswire/ - Reindeer Medical today announced its self-developed fully human dual target CD19/CD22 chimeric antigen receptor autologous T cell injection (CT120) I / Phase II registration clinical trial, the first patient enrollment and apheresis have been completed, and it is planned to be used for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL)

This study is a phase I/II, multi-center clinical study (registration number: CTR20212328).

Zhou Jianfeng, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, the main investigator of the study, said:

"This clinical trial has greatly reduced the financial burden of patients, giving patients the possibility of benefiting from new drugs one step in advance.

Dr.

“On October 13th this year, we got the approval from the National Genetics Office for this project.

About CT120

CT120 is a fully human-derived chimeric antigen receptor T cell injection targeting CD19 and CD22.

About NHL

Lymphoma originates from cells of the immune system and can endanger any organ in the body, accompanied by complex pathological processes

About Reindeer Medical

Reindeer Medical is an innovative biopharmaceutical company focusing on cell therapy and antibody drug development and industrialization

With a strong executive management team, rich product pipeline, unique innovative R&D and business model, Reindeer Medical is committed to becoming an influential innovative pharmaceutical company in the industry, and will promote innovative drugs that truly solve clinical pain points and have market competitiveness.

Source: Reindeer Medical